- |||||||||| Enrollment closed, Trial completion date, Trial primary completion date: PACE: Prostate Advances in Comparative Evidence (clinicaltrials.gov) - Jan 19, 2024
P3, N=2205, Active, not recruiting, Trial primary completion date: Sep 2021 --> Dec 2025 | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Dec 2027
- |||||||||| Enrollment change, Trial withdrawal: Clinical and Pathologic Studies in Neuroendocrine Tumors (clinicaltrials.gov) - Nov 28, 2023
P=N/A, N=0, Withdrawn, Trial primary completion date: Sep 2021 --> Dec 2025 | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Dec 2027 N=200 --> 0 | Terminated --> Withdrawn
- |||||||||| hydroxychloroquine / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Combination therapy, Surgery, Pre-surgery: PO1101944: Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas (clinicaltrials.gov) - May 1, 2019 P1/2, N=35, Completed, Active, not recruiting --> Completed | N=30 --> 17 Active, not recruiting --> Completed
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
Trial completion date, Trial termination, PD(L)-1 Biomarker, Metastases: Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer (clinicaltrials.gov) - May 1, 2019 P2, N=10, Terminated, Active, not recruiting --> Completed Trial completion date: May 2020 --> Nov 2018 | Active, not recruiting --> Terminated; Study did not meet first stage requirements of interim analysis
- |||||||||| Erivedge (vismodegib) / Roche
Trial completion, Combination therapy, Metastases: Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Apr 26, 2019 P2, N=98, Completed, Not yet recruiting --> Completed | Phase classification: PN/A --> P1 | N=24 --> 6 Active, not recruiting --> Completed
- |||||||||| topotecan / Generic mfg., carboplatin / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion: Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Apr 20, 2019 P1, N=48, Completed, N=300 --> 191 | Suspended --> Terminated; Improving assay methods Active, not recruiting --> Completed
- |||||||||| Trial completion, Metastases: Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach (clinicaltrials.gov) - Apr 20, 2019
P2, N=61, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Metastases: Gastric Cancer RAD001 Study (clinicaltrials.gov) - Apr 20, 2019 P1/2, N=35, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Dec 2019 --> Mar 2019
- |||||||||| Signifor LAR (pasireotide long acting release) / Recordati
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (clinicaltrials.gov) - Apr 20, 2019 P1, N=18, Completed, Active, not recruiting --> Completed | N=60 --> 104 Active, not recruiting --> Completed | Trial completion date: May 2020 --> Sep 2018 | Trial primary completion date: May 2020 --> Sep 2018
- |||||||||| Trial completion, Preclinical, Enrollment change: Optical Polyp Testing for In Vivo Classification (clinicaltrials.gov) - Apr 16, 2019
P=N/A, N=13, Completed, Recruiting --> Completed | N=30 --> 11 Recruiting --> Completed | N=20 --> 13
- |||||||||| Phase classification, Trial completion date, Trial termination, Trial primary completion date: Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study (clinicaltrials.gov) - Mar 19, 2019
P1, N=1, Terminated, Phase classification: P=N/A --> P1 | N=20 --> 0 | Recruiting --> Withdrawn Phase classification: P=N/A --> P1 | Trial completion date: Aug 2019 --> Mar 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Mar 2018; Closed early due to poor accrual.
- |||||||||| enzalutamide capsule / Generic mfg.
Trial completion, Trial completion date: Enzalutamide in Patients With High-risk Prostate Cancer (clinicaltrials.gov) - Mar 12, 2019 P2, N=42, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Mar 2019 --> Apr 2017
|